Compare Manchester United PLC (MANU) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manchester United PLC vs Novo Nordisk A/S — how do they compare? Manchester United PLC trades at $22.08 (market cap $3.80B), while Novo Nordisk A/S trades at $49.35 (market cap $220.53B). The key difference: Novo Nordisk A/S is far larger — about 58× Manchester United PLC's market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| MANU | NVO | |
|---|---|---|
Market Cap | $3.80B | $220.53B |
Sector | Media | Health |
52-Week High | $23.53 | $71.70 |
52-Week Low | $15.10 | $35.29 |
Enterprise Value | $4.72B | $239.49B |
Dividend Yield | 1.26% | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manchester United (MANU) trades at $22.45, up 0.99% on the day, with a neutral technical signal and mixed earnings performance. The company reported a net loss of $33.02M for 2025, though revenue grew to $666.51M. Recent news highlights progress on a new 100,000-seat stadium and Champions League qualification, which may boost future revenue. The stock's valuation shows a P/S of 4.21 and negative ROE of -6.36%, reflecting profitability challenges amid strategic investments.
The outlook is cautiously optimistic, driven by stadium development and sports performance, but high debt and inconsistent earnings pose risks. Analysts are mixed with 40% buy ratings. Investors should weigh growth initiatives against financial leverage and margin pressures.
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
